Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3032 in Healthy Participants and Participants With Overweight or Obesity
NCT07160400Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Sep 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3032 in obesity (4 arms), sponsored by Innovent Biologics. Primary endpoints: Number of Participants with adverse events at Day 43 and Number of Participants with Serious Adverse Events at Day 43. Started Sep 2025; status: completed.
02
Drugs
IBI3032
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07160400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07160400.